{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T01:34:51Z","timestamp":1790386491805,"version":"4.1.0"},"reference-count":15,"publisher":"The Endocrine Society","issue":"9","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2012,9,1]]},"abstract":"<jats:sec><jats:title>Context:<\/jats:title><jats:p>Glucokinase is expressed in the hypothalamus, but effects of glucokinase activators (GKAs) on counterregulatory responses to hypoglycemia are unknown.<\/jats:p><\/jats:sec><jats:sec><jats:title>Objective:<\/jats:title><jats:p>Two separate studies assessed the counterregulatory hormone responses to hypoglycemia induced by the GKAs, AZD6370 and AZD1656, compared with insulin infusion.<\/jats:p><\/jats:sec><jats:sec><jats:title>Design and Setting:<\/jats:title><jats:p>Both studies were randomized, open, two-way crossover studies, conducted in separate clinical research centers.<\/jats:p><\/jats:sec><jats:sec><jats:title>Participants:<\/jats:title><jats:p>Both studies involved 12 healthy adult male volunteers.<\/jats:p><\/jats:sec><jats:sec><jats:title>Interventions:<\/jats:title><jats:p>Each subject received two treatments in randomized order, separated by a washout. In the AZD6370 study, overnight-fasted subjects received either a single oral AZD6370 dose (300 mg) or insulin infusion (0.8 mU\/kg \u00b7 min). In the AZD1656 study, overnight-fasted subjects received either a single oral dose of AZD1656 (80 mg) plus supporting insulin (1 mU\/kg \u00b7 min) or insulin alone (1 mU\/kg \u00b7 min). Insulin was added to support AZD1656 because AZD1656 alone did not produce the desired hypoglycemia. Plasma glucose was lowered during a stepwise hypoglycemic clamp with a glycemic nadir of 2.7 mmol\/liter for 30 min.<\/jats:p><\/jats:sec><jats:sec><jats:title>Main Outcome Measures:<\/jats:title><jats:p>Epinephrine, norepinephrine, GH, cortisol, and glucagon plasma levels were assessed.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results:<\/jats:title><jats:p>No safety issues were raised. AZD6370 and AZD1656 had no effect on counterregulatory responses for norepinephrine, GH, or cortisol, but epinephrine increased slightly with AZD1656. Glucagon responses were reduced by approximately 30% with both GKAs vs. insulin.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions:<\/jats:title><jats:p>These data suggest the central nervous system-mediated counterregulatory response during GKA-induced hypoglycemia was preserved, whereas the glucagon response was attenuated; the latter was possibly mediated by a local pancreatic effect (intraislet hyperinsulinemia) rather than by impairment of the central nervous system-mediated response.<\/jats:p><\/jats:sec>","DOI":"10.1210\/jc.2012-1496","type":"journal-article","created":{"date-parts":[[2012,6,22]],"date-time":"2012-06-22T15:48:55Z","timestamp":1340380135000},"page":"3319-3325","source":"Crossref","is-referenced-by-count":24,"title":["Glucokinase Activators AZD6370 and AZD1656 Do Not Affect the Central Counterregulatory Response to Hypoglycemia in Healthy Males"],"prefix":"10.1210","volume":"97","author":[{"given":"Ensio","family":"Norjavaara","sequence":"first","affiliation":[{"name":"Division of Research and Development (E.N., H.E., M.L.-Z., M.S.), AstraZeneca, 431 83 M\u00f6lndal, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hans","family":"Ericsson","sequence":"first","affiliation":[{"name":"Division of Research and Development (E.N., H.E., M.L.-Z., M.S.), AstraZeneca, 431 83 M\u00f6lndal, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Folke","family":"Sj\u00f6berg","sequence":"first","affiliation":[{"name":"Department of Clinical and Experimental Medicine (F.S.), Link\u00f6ping University, 581 83 Link\u00f6ping, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Leonsson-Zachrisson","sequence":"first","affiliation":[{"name":"Division of Research and Development (E.N., H.E., M.L.-Z., M.S.), AstraZeneca, 431 83 M\u00f6lndal, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mikaela","family":"Sj\u00f6strand","sequence":"first","affiliation":[{"name":"Division of Research and Development (E.N., H.E., M.L.-Z., M.S.), AstraZeneca, 431 83 M\u00f6lndal, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linda A.","family":"Morrow","sequence":"first","affiliation":[{"name":"Profil Institute for Clinical Research (L.A.M., M.H.), Chula Vista, California 91911"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcus","family":"Hompesch","sequence":"first","affiliation":[{"name":"Profil Institute for Clinical Research (L.A.M., M.H.), Chula Vista, California 91911"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"80","reference":[{"key":"2020071613130670800_B1","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1007\/s00018-008-8322-9","article-title":"Molecular physiology of mammalian glucokinase.","volume":"66","author":"Iynedjian","year":"2009","journal-title":"Cell Mol Life Sci"},{"key":"2020071613130670800_B2","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1038\/nrd2850","article-title":"Assessing the potential for glucokinase activators in diabetes therapy.","volume":"8","author":"Matschinsky","year":"2009","journal-title":"Nat Rev Drug Discov"},{"key":"2020071613130670800_B3","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1517\/13543784.17.2.145","article-title":"Glucokinase activators in diabetes management.","volume":"17","author":"Coghlan","year":"2008","journal-title":"Expert Opin Investig Drugs"},{"key":"2020071613130670800_B4","doi-asserted-by":"crossref","first-page":"3641","DOI":"10.1016\/S0021-9258(17)41910-7","article-title":"Analysis of upstream glucokinase promoter activity in transgenic mice and identification of glucokinase in rare neuroendocrine cells in the brain and gut.","volume":"269","author":"Jetton","year":"1994","journal-title":"J Biol Chem"},{"key":"2020071613130670800_B5","doi-asserted-by":"crossref","first-page":"2056","DOI":"10.2337\/diabetes.51.7.2056","article-title":"Glucokinase is the most likely mediator of glucosensing in both glucose-excited and glucose-inhibited central neurons.","volume":"51","author":"Dunn-Meynell","year":"2002","journal-title":"Diabetes"},{"key":"2020071613130670800_B6","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.2337\/db07-1755","article-title":"Ventromedial hypothalamic glucokinase is an important mediator of the counterregulatory response to insulin-induced hypoglycaemia.","volume":"57","author":"Levin","year":"2008","journal-title":"Diabetes"},{"key":"2020071613130670800_B7","doi-asserted-by":"crossref","first-page":"R784","DOI":"10.1152\/ajpregu.00645.2007","article-title":"Prior hypoglycemia enhances glucose responsiveness in some ventromedial hypothalamic glucosensing neurons.","volume":"294","author":"Kang","year":"2008","journal-title":"Am J Physiol Regul Integr Comp Physiol"},{"issue":"1 Pt 1","key":"2020071613130670800_B8","first-page":"E67","article-title":"Hierarchy of glycemic thresholds for counterregulatory hormone secretion, symptoms, and cerebral dysfunction.","volume":"260","author":"Mitrakou","year":"1991","journal-title":"Am J Physiol"},{"key":"2020071613130670800_B9","doi-asserted-by":"crossref","first-page":"2397","DOI":"10.2337\/diabetes.53.9.2397","article-title":"Effect of intravenous infusion of exenatide (synthetic extendin-4) on glucose-dependent insulin secretion and counterregulation during hypoglycaemia.","volume":"53","author":"Degn","year":"2004","journal-title":"Diabetes"},{"key":"2020071613130670800_B10","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1016\/0024-3205(78)90665-3","article-title":"A sensitive method for the determination of plasma catacholamines using liquid chromatography with electrochemical detection.","volume":"23","author":"Hallman","year":"1978","journal-title":"Life Sci"},{"key":"2020071613130670800_B11","doi-asserted-by":"crossref","first-page":"958","DOI":"10.2337\/diabetes.51.4.958","article-title":"Intraislet hyperinsulinemia prevents the glucagon response to hypoglycemia despite an intact autonomic response.","volume":"51","author":"Banarer","year":"2002","journal-title":"Diabetes"},{"key":"2020071613130670800_B12","doi-asserted-by":"crossref","first-page":"95","DOI":"10.2337\/diacare.6.1.95","article-title":"Relevance of glucose counterregulatory systems to patients with diabetes: critical roles of glucagon and epinephrine.","volume":"6","author":"Cryer","year":"1983","journal-title":"Diabetes Care"},{"key":"2020071613130670800_B13","doi-asserted-by":"crossref","first-page":"3592","DOI":"10.2337\/diabetes.54.12.3592","article-title":"Mechanisms of hypoglycemia-associated autonomic failure and its component syndromes in diabetes.","volume":"54","author":"Cryer","year":"2005","journal-title":"Diabetes"},{"key":"2020071613130670800_B14","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1038\/sj.bjp.0706848","article-title":"Predictive blood glucose lowering efficacy by glucokinase activators in high fat fed female Zucker rats.","volume":"149","author":"Coope","year":"2006","journal-title":"Br J Pharmacol"},{"key":"2020071613130670800_B15","doi-asserted-by":"crossref","first-page":"5028","DOI":"10.1210\/jc.2010-1041","article-title":"Piragliatin (RO4389620), a novel glucokinase activator, lowers plasma glucose both in the postabsorptive state and after a glucose challenge in patients with type 2 diabetes mellitus: a mechanistic study.","volume":"95","author":"Bonadonna","year":"2010","journal-title":"J Clin Endocrinol Metab"}],"container-title":["The Journal of Clinical Endocrinology &amp; Metabolism"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/jcem\/article-pdf\/97\/9\/3319\/9048782\/jcem3319.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/jcem\/article-pdf\/97\/9\/3319\/9048782\/jcem3319.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,1,19]],"date-time":"2022-01-19T08:38:13Z","timestamp":1642581493000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jcem\/article\/97\/9\/3319\/2537078"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,9,1]]},"references-count":15,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2012,9,1]]}},"URL":"https:\/\/doi.org\/10.1210\/jc.2012-1496","relation":{},"ISSN":["0021-972X","1945-7197"],"issn-type":[{"value":"0021-972X","type":"print"},{"value":"1945-7197","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,9,1]]}}}